
CRISIL reaffirms Mankind Pharma AA+ on NCDs, withdraws two ratings
Two debenture ratings stay at Crisil AA+/Stable, while the ₹2,500 crore debenture rating and the ₹1,500 crore commercial paper rating are withdrawn.
- Credit rating
Every Mankind Pharma Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: mergers & acquisitions, credit rating, earnings.
4 articles · Pharmaceuticals · Latest 30 Oct 2026

Two debenture ratings stay at Crisil AA+/Stable, while the ₹2,500 crore debenture rating and the ₹1,500 crore commercial paper rating are withdrawn.
Scheme 1 merges Prolijune Lifesciences and Pavi Buildwell into the listed company with no new shares issued. Appointed date 1 Apr 2027, subject to NCLT approval.

Mankind Pharma (NSE: MANKIND) reported consolidated total income of ₹4,432.71 crore and net profit of ₹716.12 crore for the quarter ended 30 Sep 2026, it said in a filing on 26 Oct 2026. Standalone total income was ₹3,204.05 crore and standalone net profit ₹581.95 crore for the same quarter.

Mankind Pharma Limited has told the exchanges that its board, at a meeting on 15 Oct 2026, approved an additional investment of up to €45 million in its wholly owned Netherlands subsidiary, Mankind Pharma (Netherlands) B.V., in one or more tranches. That raises the aggregate investment limit to €50 million, including the €5 million approved earlier.